Minireviews
Copyright ©The Author(s) 2019.
World J Gastrointest Surg. Jun 27, 2019; 11(6): 279-286
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.279
Table 1 Papers about neoadjuvant therapy before resection considered in this review
AuthorYrType of studyPatients treated with NA RCTResectabilityNeoadjuvant regimen% of R0 (R0/resected)Results achievedConclusions
McMasters at al[11]1997Non randomized, prospective5 hCCA and 4 dCCAAll unresectable5-FU at 300 mg/m2, EBRT to 50.4 or 45 Gy100% (9/9)Recurrence for hCCA: 0%NA RCT can safely allow R0 resection.
Nelson et al[14]2009Retrospective12 (hCCA and dCCA)10 unresectable5-FU, EBRT to 50.4 Gy (11/12) ± brachitherapy (5/12)91% (11/12)Better trend in 5-yr survival rate for NA RCT groupNA RCT can safely allow R0 resection.
Jung et al[15]2015Retrospective12, all hCCAAll unresectable5-FU/Gemcitabine, EBRT to 50.4 or 45 Gy83,3% (10/12)Better R0 rate for NA RCT group; no advantage in DFS and OSNA RCT can safely allow R0 resection, without improving DFS and OS.
Sumiyoshi et al[16]2018Retrospective8 hCCAAll unresectableS-1, EBRT to 50 Gy71,4% (5/7)Better DFS and OS for patients who underwent surgery after downstaging with NA RCTNA RCT can safely allow R0 resection, improved DFS and OS for patients operated.
Katayose et al[18]2015Non randomized, prospective24 (hCCA and dCCA)All advanced, possibly resectableGemcitabine 600 mg/m2, EBRT to 45 Gy80,9 % (17/21)R0 rate: 80.9% of patients operated, 70.8% of all patients enrolledNA RCT followed by surgery effective and well tolerated, DFS and OS yet to determine.
Tada et al[19]2012Case report1 hCCAUnresectableGemcitabine + S-11/1R0 resection with portal resection, no recurrence at 29 moNA CT can allow R0 resection.
Sano et al[20]2011Case report1 hCCAUnresectableGemcitabine1/1R0 resection with portal and arterial resection, no recurrence at 18 moNA CT can allow R0 resection.